Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of irofulven in treating patients who have
recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die.